ArticleFrontiers in immunology2026
Mass drug administration of praziquantel lowers the susceptibility of school-aged children to
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schistosomiasis remains a significant public health challenge in endemic regions, leading to substantial morbidity. While regular mass drug administration (MDA) of praziquantel (PZQ) is a cornerstone schistosomiasis control programs in endemic areas, emerging evidence suggests that its benefits may extend beyond mere parasite killing. we sought to determine whether sustained PZQ MDA promotes the development of protective immunity in school-aged children. Building on previous observations in animal models where repeated cycles of Methods: We performed a cross-sectional study on previously collected samples from school-aged children in schistosomiasis-endemic regions who received repeated MDA of PZQ. Levels of plasma antibodies and cytokines were measured by ELISA. Results: Analysis of previously collected samples and data from cumulative annual rounds of PZQ treatment demonstrated that regular administration significantly reduced the odds of elevated parasite burdens upon reinfection (AOR = 0.16, 95% CI = 0.01-0.61), and improved hemoglobin levels (AOR = 2.58, 95% CI = 1.22-8.05) and academic performance (AOR = 2.39, 95% CI = 1.11-7.09) in SAC. However, it did not significantly reduce the likelihood of liver fibrosis (AOR = 1.73, 95% CI = 0.45-14.53). Mechanistically, repeated PZQ treatment of SAC was associated with heightened arginine/proline metabolism that translated into higher protective IgE levels (p = 0.002) and increased type-2 cytokine production. Conclusion: Our study highlights a previously underappreciated advantage of sustained PZQ treatment in SAC from schistosomiasis-endemic areas. Regular deworming with PZQ may rapidly rewire the host to foster the development of protective immune responses, mitigating the risks of heavy reinfection and its sequelae, underscoring the overlooked benefits of PZQ treatment for integrated public health strategies against schistosomiasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.